The first half of 2026 is delivering a clear signal to boardrooms across Europe and the Americas: cross-border mergers and acquisitions are not slowing down. From private equity-backed infrastructure expansions in Latin America to European pharma consolidating U.S. biotech assets, the deal landscape is reshaping competitive dynamics across multiple sectors simultaneously. For CFOs, General Counsel, and M&A Directors, understanding the structural forces behind this wave is no longer optional — it is a prerequisite for strategic positioning.

Infrastructure M&A: Data Centers and Fiber Networks Attract Institutional Capital

The acquisition of Elea Data Centers by I Squared Capital stands as one of the most instructive transactions of the current cycle. Elea operates nine carrier-neutral campuses in Brazil, serving both enterprise and hyperscale customers — a profile that has become increasingly attractive to infrastructure-focused private equity as AI workloads drive exponential growth in data demand across emerging markets. Latin America, long underserved in digital infrastructure relative to its economic footprint, is now a primary destination for institutional capital seeking yield and long-term contracted revenue.

Simultaneously, the divestiture of Metronet by Oak Hill Capital to a T-Mobile and KKR joint venture underscores how fiber-to-the-home assets are being repositioned within larger connectivity ecosystems. Mid-market infrastructure deals of this nature require sophisticated due diligence frameworks — particularly around regulatory approvals, spectrum rights, and local authority concessions — that differ materially from traditional corporate finance transactions.

  • Key consideration: Cross-border infrastructure acquisitions in regulated markets demand early engagement with antitrust authorities and sector-specific regulators, particularly in jurisdictions with foreign investment screening mechanisms such as Brazil’s CADE or the EU’s FDI Regulation (EU) 2019/452.
  • Due diligence priority: Contractual revenue visibility, hyperscaler anchor tenants, and power procurement agreements are now primary value drivers — not just EBITDA multiples.

Pharma and Diagnostics: European Acquirers Target U.S. Innovation Assets

Belgian pharmaceutical group UCB’s agreement to acquire U.S.-based Neurona Therapeutics for up to $1.15 billion exemplifies a broader pattern: European strategics deploying capital into American biotech to access clinical-stage pipelines that would take years and significant R&D investment to replicate organically. This cross-border deal structure — milestone-based consideration with upfront cash — is now the dominant template in life sciences M&A, balancing acquirer risk with founder and investor upside.

In parallel, CareDx’s acquisition of Naveris, a precision oncology diagnostics firm specialising in blood-based minimal residual disease (MRD) surveillance, reflects the convergence of transplant medicine and oncology under a single corporate umbrella. As reimbursement frameworks for liquid biopsy technologies mature — particularly under CMS coverage determinations in the United States — these assets are attracting premium valuations that demand rigorous post-merger integration planning to preserve clinical credibility and regulatory standing.

  • Regulatory watch: Cross-border pharma and diagnostics deals involving U.S. targets are subject to CFIUS review where dual-use technology or genomic data is involved. European acquirers should conduct CFIUS risk assessments at the letter-of-intent stage.
  • Valuation discipline: Milestone-contingent structures require General Counsel to stress-test earn-out definitions against clinical trial endpoints and regulatory approval timelines.

Private Equity as the Structural Engine of Mid-Market Expansion

Across insurance, connectivity, and AI-enabled operations, private equity and venture capital firms are functioning as the primary architects of sector consolidation. Protective Life Corporation’s acquisition of Obsidian Insurance Holdings from Genstar Capital illustrates how PE-backed platforms are being harvested into strategic buyers seeking to diversify product lines — in this case, expanding from life insurance into specialty property and casualty markets.

For board members evaluating inbound acquisition interest or preparing portfolio companies for exit, the current environment rewards operational readiness: clean data rooms, audited financial statements aligned with IFRS or US GAAP, and documented compliance programmes that withstand accelerated due diligence timelines driven by competitive auction processes.

Implications for Decision-Makers

The 2026 deal environment presents both opportunity and execution risk. Three priorities should be on every M&A Director’s agenda:

  • Jurisdiction mapping: Identify foreign investment screening obligations early — the EU, UK, and Brazil have each expanded FDI review scope since 2022.
  • Integration architecture: Post-merger integration in technology-intensive acquisitions (data centers, diagnostics platforms) must address data governance and cybersecurity from day one, not as an afterthought.
  • Financing structure: With interest rate environments stabilising across the Eurozone and the U.S., leveraged buyout structures are returning — but lenders are applying stricter covenant packages than in the 2020–2022 cycle.

Key Takeaway

Cross-border M&A in 2026 is being driven by structural demand — for digital infrastructure, precision medicine, and specialty financial products — rather than purely financial arbitrage. For European executives and their advisors, the window to act on high-quality assets in the Americas and in U.S. biotech remains open, but execution quality, regulatory foresight, and disciplined corporate finance structuring will determine which transactions create lasting value and which become cautionary case studies in post-merger integration failure.